Breaking News
December 14, 2018 - Researchers discover Ebola-fighting protein in human cells
December 14, 2018 - Fentanyl surpasses heroin in cause of U.S. drug overdose deaths
December 14, 2018 - When Heart Attack Strikes, Women Often Hesitate to Call for Help
December 14, 2018 - A warning about costume contacts
December 14, 2018 - Study examines link between peripheral artery disease and heart attack
December 14, 2018 - Researchers develop biotechnological tool to produce antifungal proteins in plants
December 14, 2018 - 3D-printed adaptive aids can benefit patients with arthritis
December 14, 2018 - Chronic bullying during adolescence impacts mental health
December 14, 2018 - Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics
December 13, 2018 - Importance of cell cycle and cellular senescence in the placenta discovered
December 13, 2018 - Gold “nanoprisms” open new window into vessels and single cells
December 13, 2018 - Research findings could lead to new targets for cancer-fighting therapeutics
December 13, 2018 - Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines
December 13, 2018 - Study explores how patients want to discuss symptoms with doctors
December 13, 2018 - RUDN medics first to gather scattered data on hepatitis morbidity in Somalia
December 13, 2018 - Age and gender disparities found in use of bed nets to prevent malaria in sub-Saharan Africa
December 13, 2018 - Caffeine therapy benefits developing brains of premature babies
December 13, 2018 - New review focuses on electrospinning techniques used in musculoskeletal tissue engineering
December 13, 2018 - A new division focused on human immune system
December 13, 2018 - Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of Fintepla (ZX008) in Dravet Syndrome
December 13, 2018 - BCR ABL Genetic Test: MedlinePlus Lab Test Information
December 13, 2018 - Caffeinated beverages during pregnancy linked to lower birth weight babies
December 13, 2018 - Stanford Medicine Health Trends Report examines opportunity to democratize health care
December 13, 2018 - Obsessive-compulsive disorder may protect individuals from obesity
December 13, 2018 - Scientists investigate how a painful event is processed in the brain
December 13, 2018 - Genetic study reveals new insights into underlying causes of moderate-to-severe asthma
December 13, 2018 - Vitamin C supplementation for pregnant smokers may reduce harm to infants’ lungs
December 13, 2018 - New study reveals yin-yang personality of dopamine
December 13, 2018 - Research identifies nerve-signaling pathway behind sustained pain after injury
December 13, 2018 - Children with high levels of callous traits show widespread differences in brain structure
December 13, 2018 - Long-term Benefit of Steroid Injections for Knee Osteoarthritis Challenged
December 13, 2018 - Adding new channels to the brain remote control
December 13, 2018 - In the Spotlight: A different side of neuroscience
December 13, 2018 - Medical Marvels: Using immunotherapy for melanoma that spread to the brain
December 13, 2018 - Puzzles do not keep dementia away finds study
December 13, 2018 - New mouse model shows potential for rapid identification of promising muscular dystrophy therapies
December 13, 2018 - Study reveals urban and rural differences in prenatal exposure to essential and toxic elements
December 13, 2018 - New collaborative partnership in quest of novel antibiotics
December 13, 2018 - Single tau molecule holds clues to help diagnose neurodegeneration in its earliest stages
December 13, 2018 - AHA Scientific Statement: Low Risk of Side Effects for Statins
December 13, 2018 - What Is Acute Flaccid Myelitis?
December 13, 2018 - How bereaved people control their thoughts without knowing it
December 13, 2018 - Health care democratization underway, according to 2nd annual Stanford Medicine Health Trends Report | News Center
December 13, 2018 - Going Beyond a Single Color
December 13, 2018 - London-based startup launches ‘thedrug.store’ aiming to clean up CBD industry
December 13, 2018 - Loss of tight junction barrier protein results in gastric cancer development
December 13, 2018 - Novel way to efficiently deliver anti-parasitic medicines
December 13, 2018 - RKI publishes new data on disease prevention and utilization of medical services
December 13, 2018 - High-tech, flexible patches sewn into clothes could help to stay warm
December 13, 2018 - The CCA releases three reports on requests for medical assistance in dying
December 13, 2018 - Restoring Hair Growth on Scarred Skin? Mouse Study Could Show the Way
December 13, 2018 - Probiotic use may reduce antibiotic prescriptions, researchers say
December 13, 2018 - Drug repositioning strategy identifies potential new treatments for epilepsy
December 13, 2018 - Chronic rhinitis associated with hospital readmissions for asthma and COPD patients
December 13, 2018 - Food poisoning discovery could save lives
December 13, 2018 - Cloned antibodies show potential to treat, diagnose life-threatening fungal infections
December 13, 2018 - Exercise may reduce colorectal cancer risk after weight loss
December 13, 2018 - Russian scientists create hardware-information system for brain disorders treatment
December 13, 2018 - Moderate alcohol consumption linked with lower risk of hospitalization
December 13, 2018 - Nurturing Healthy Neighborhoods | NIH News in Health
December 13, 2018 - Rise in meth and opioid use during pregnancy
December 13, 2018 - Researchers gain new insights into pediatric tumors
December 13, 2018 - FSU study finds racial disparity among adolescents receiving flu vaccine
December 13, 2018 - Study investigates attitudes toward implementation of ‘sex as a biological variable’ policy
December 13, 2018 - Drug cocktail induces cancer cell death by switching off energy supply
December 13, 2018 - Baculovirus virion completely eliminates liver-stage parasites in mouse model
December 13, 2018 - Researchers create noninvasive technology that detects when nerve cells fire
December 13, 2018 - Allen Institute for Immunology to partner with CU Anschutz to understand dynamics of human immune system
December 13, 2018 - Inability to do daily living tasks delays discharge of mental health patients
December 13, 2018 - Treating patients with hypertension induced albuminuria
December 13, 2018 - New substance could improve efficacy of established breast cancer treatments
December 13, 2018 - Scientists develop new stem cell line to study conversion of stem cells into muscle
December 13, 2018 - Re-programming the body’s energy pathway boosts kidney self-repair
December 13, 2018 - Research findings could help improve treatment of anxiety and post-traumatic stress disorders
December 13, 2018 - The Microbiome Movement announce Microbiotica as official industry partner
December 13, 2018 - New study reveals potential benefits of cEEG monitoring for infant ICU patients
December 13, 2018 - Whole-body imaging PET/MRI offers information to guide treatment options for prostate cancer
December 13, 2018 - International investigators fight against the negative campaign on benzodiazepines
December 13, 2018 - Targeting biochemical pathway may lead to new therapies for alleviating symptoms of anxiety disorders
December 13, 2018 - FDA Approves Tolsura (SUBA®-itraconazole capsules) for the Treatment of Certain Fungal Infections
Not all genetic tests should be publicly funded — here’s why

Not all genetic tests should be publicly funded — here’s why

image_pdfDownload PDFimage_print
More knowledge about your genetic makeup enables you to make better-informed choices – but at what cost? Credit: Shutterstock

New genetic technologies hold great promise in their potential to treat patients based on their individual genetic information. Advances in mapping the human genome mean the cost of doing a genetic test has fallen dramatically, though the costs of these tests – and subsequent treatment – are still high.

It’s exciting to think we’re on the brink of a genomic revolution in health care. But just because new technology becomes available, it doesn’t mean it should automatically be funded by the government through Medicare or the Pharmaceutical Benefits Scheme (PBS).

A number of types of genetic tests are currently available, including those for:

a person’s whole genome sequencea particular gene that carries the certainty of a diagnosisa gene that increases the person’s risk of developing a diseasea patient who already has a diagnosis, to test whether a particular medicine will be effective.

Each genetic test, each disease and each treatment pathway must be analysed to determine the balance of costs and benefits. We need to apply the same principles we do for any test, procedure or new medicine to determine whether it should be publicly funded: it must represent good value for money and be likely to improve health outcomes.

Gene-based therapies

Let’s consider the example of cancer treatment. Some medicines work only on tumours with particular genetic markers. By using a test to target the medicine only to cancer patients who have the marker, we can be more confident that the medicine is effective for those who are treated, thus avoiding unnecessary costs and possible side-effects. This could make the new medicine more affordable.

But for the seller of the medicine, greater effectiveness means they can ask a higher price. Indeed, they need to, because now there is a smaller target “market”.

The cystic fibrosis drug Ivacaftor, for instance, cost patients around A$250,000 a year before it was subsidised on the PBS. The clinical trials had only demonstrated effectiveness in patients with a G551D mutation, which is only 8.6% of the population with the disease.

The challenge for the government is whether we can afford to pay higher prices for each of these targeted medicines. Then there’s the issue of who will pay for the test, which will need to be done for everyone who might have the genetic marker. Should it be the government, private health insurers or individuals?

Without public funding of genetic testing, access to the effective treatment depends on whether you can afford to pay for the test, which undermines the equity principles of Medicare.

To overcome this challenge, Australia now requires integrated submissions of “co-dependent” technologies. This means, for instance, that if access to a new medicine on the PBS depends on the results of a test, the test should be publicly funded, and at a price that represents good value for money.

Testing for known diseases

More knowledge about your genetic makeup enables you to make better-informed choices: whether to seek preventive treatment; to change your behaviour to reduce risks; or to plan for the future.

In the context of specific known diseases, such testing is best done in a setting with genetic counselling, so the person can fully understand the implications of the knowledge and the decisions that may need to be made.

For a woman who has had breast cancer, a BRCA gene test can inform her choice about, for example, mastectomy to prevent a second breast cancer. Testing of immediate family members can determine if they carry the gene, allowing them to seek preventive treatment or more frequent screening.

But sometimes nothing can be done with the knowledge you obtained from your gene test. Knowing you have a higher risk of, say, dementia, could improve your well-being by giving you the chance to plan. Or it could just make you feel worse.

The costs and benefits of a genetic test depend greatly on whether there is effective prevention or treatment available, and what that treatment is.

Value for money

Australia assesses whether any test in health care represents good value for money by mapping out the treatment pathways that are available for each test result, and evaluating the costs and health benefits of each of these.

Based on such an assessment, the Medical Services Advisory Committee recently recommended a Medicare rebate of A$1,200 for genetic testing for hereditary mutations for breast and ovarian cancer, including the BRCA1 and 2 genes. This would cover most, if not all, of the cost of the test. The committee also recommended Medicare pay a A$400 rebate for predictive testing for family members.

The committee concluded the test would be good value for money, at around A$18,000 per Quality Adjusted Life Year (QALY) gained (from breast and ovarian cancers avoided). A QALY is a way of quantifying the additional survival and quality of life from the test compared with not having the test available.

For a test for a single gene or genes that are a certain marker for specific diseases, assessment of cost effectiveness is relatively straightforward, particularly if there is an effective treatment available.

Predicting future diseases

For a test that indicates increased risk of developing diseases in the future, such as whole genome sequencing, the options are less clear.

The committee would ask: can the person reduce their risk by exercising more and eating better? And will the information increase their motivation to do so over and above medical advice already received? Or will it motivate them to seek more treatment over time? And how effective is this treatment?

Whole genome sequencing and genetic counselling is available privately in Australia now for around A$6,000 (including a health assessment) – so affordable only to the rich. It is not publicly funded because the benefits are uncertain.

It could just be “nice to know” (as such tests are marketed in the US); it could motivate the person to change their behaviour and thus lead to better health outcomes; or it could create anxiety and unnecessary intervention, and thus ultimately increase health care costs, not just for the individual but for the society.

There is no blanket answer to whether genomic testing is cost-effective. Each test, each disease and each treatment pathway must be analysed to determine the balance of costs and benefits, following the same approach as for other new medical technologies.


Explore further:
Whole-population testing for breast and ovarian cancer gene mutations is cost effective

Provided by:
The Conversation

Tagged with:

About author

Related Articles